Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — Q1 FY27 Earnings Presentation
20 slides from Viyash Scientific's earnings presentation, Aug 12, 2026
Slide 1: Viyash Scientific Limited stock exchange filing letter
Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000, E: investorrelations@viyash.com
Slide 2: Investor Presentation Q1 FY27
INVESTOR PRESENTATION Q1 FY27 V I YA S H S C I E N T I F I C L I M I T E D August 12, 2026 1
Slide 3: Marching ahead as an Integrated platform
Marching ahead as an Integrated platform Our performance in Q1 FY27 reflects the continued success of our integration efforts and the strength of the combined entity. This quarter's results are underpinned by robust execution, improving operating leverage, and a well-defined growth strategy. The acq
Slide 4: Q1FY27 Financial Snapshot
Viyash Q1FY27 Financial Snapshot
Slide 5: Q1 FY27 Performance Highlights
Viyash Scientific : Q1 FY27 Performance Highlights All values in ₹ Mn Revenues EBITDA¹ EBITDA Margin Net Debt to LTM EBITDA¹ ₹9,464 ₹2,047 21.6% 0.1x Million Million Net Debt- ₹ 861 Mn +19.5% +59.2 % +530 bps 0.2x YoY YoY YoY in Q4 FY26 Net Debt - ₹ 1,661 4 Notes: 1. EBITDA are adjusted for ESOP cos
Slide 6: Sustained Sales Growth with Consistent EBITDA Expansion
Sustained Sales Growth with Consistent EBITDA Expansion All values in ₹ Mn Sales Gross Margin 5,071 5,121 10,000 9,464 5,000 4,718 4,675 9,200 65.0% 9,000 3,971 4,075 4,111 8,503 8,584 4,000 3,741 3,580 55.5% 55.1% 55.0% 7,740 7,916 54.5% 54.1% 8,000 7,723 51.2% 51.3% 52.8% 51.9% 7,292 7,313 49.1% 3
Slide 7: Consolidated Financials
Viyash Consolidated Financials All values in ₹ Mn Q1 Q1 Grw Q4 Grw Grw Particulars FY26 FY25 FY27 FY26 YoY % FY26 QoQ % YoY % Revenue from Operations 9,464 7,916 19.5% 9,200 2.9% 34,203 30,068 13.8% Material Consumption (4,343) (3,805) (4,128) (15,627) (14,702) Gross Margin 5,121 4,111 24.6% 5,071 1
Slide 8: Business Updates
Viyash Business Updates
Slide 9: Business Segments Performance
Business Segments Performance All values in ₹ Mn Q1 Q4 12M Revenue Distribution FY27 FY26 YoY % FY26 QoQ % FY26 FY25 YoY % Formulations 5,547 4,170 33% 4,991 11% 18,657 15,828 18% Europe 1,847 1,640 13% 1,733 7% 6,682 5,614 19% Emerging Markets 2,008 1,480 36% 1,725 16% 6,305 5,142 23% India 430 263
Slide 10: Bio For Life acquisition in Italy
Bio For Life acquisition in Italy Acquisition of Bio for Life in Italy aligned with our Companion strategy Companion animal portfolio Provides access to a large (85-90 products) that can be 01 companion animal market 02 extended to other core in Italy markets Launch our global pipeline in Strong tal
Slide 11: Additional Business Updates
Additional Business Updates Facility Inspections Regulatory Approvals Launches 4 Regulatory Audits 3 APIs- (USDMF-1 ; EDMF- 6 APIs ( 2-MENA, 1-EU, 1 1; CEP-1) CHINA, 1 LATAM) 66 Customer audits 2 FDF - US (2) 4 FDF Products Filed Validations Completed R&D Pipeline 8 APIs – USDMF (1),USVMF(1), 15 API
Slide 12: Viyash at a Glance
Viyash Viyash ata Glance
Slide 13: Who we are?
Who we are? We are an integrated pharmaceutical platform across animal and human health backed by science and IP Diversified Product Global Presence Backward IP & Technology Strong Management Portfolio Integration Driven Team API - 90+ 150+ Countries 16 Manufacturing facilities 250+ Scientists Indus
Slide 14: Viyash Scientific: Key Milestones
Viyash Scientific: Key Milestones Viyash Life Sciences Foundation & Early Growth Scale & Expansion Integration & Global Reach Founded in February 2019 by Acquisition of Mylan's API and formulation Unified manufacturing operations, Dr Haribabu Bodepudi. units in Vizag and Mumbai. Strategic expanded R
Slide 15: 16 world class manufacturing facilities
16 world class manufacturing facilities Turkey USA Spain 10 API MANUFACTURING Brazil I SITES India – AH Formulations Brazil II API Formulations
Slide 16: Our R&D landscape
Our R&D landscape Turkey Spain India • Animal Formulations • Human Formulations • API Brazil R&D centre Location Capabilities / dosage forms Technologies & infrastructure R&D members • Scalable complex APIs incl. high-potent (OEB • 20+ chemical R&D labs; dedicated process- India (Hyderabad, API R&D
Slide 17: Board of Directors
Board of Directors Dr. Haribabu Mr. Rajaram Mr. Anuj Poddar Mr. Amit Jain Bodepudi Narayanan Non-executive Director Non-executive Director Managing Director and Executive Director and Group CEO CEO- Animal Health Dr. Kamal Sharma Chairman and Independent Director Mr. Srinivas Mr. Abhiroop Ms. Revati
Slide 18: Growth drivers
Growth drivers Long Term Strategy ✓ New product development Companion Animals ✓ Market expansion ✓ Manufacturing expansion ✓ M&A Animal formulations Farm Animals ✓ Portfolio completion ✓ Geography extension ✓ Portfolio expansion ✓ Day 1 launch API & CDMO ✓ Complex CDMO ✓ API integrated play Human fo
Slide 19: For details, feel free to contact
For details, feel free to contact: Yoshita Vora Abhishek Singhal Company Secretary Investor Relations Consultant +91 22 4111 4777 abhishek@arunya.co.in investorrelations@viyash.com Registered Office: Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 50008
Slide 20: Thank You
Thank You Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 500081, India info@viyash.com | www.viyash.com Copyright © 2021. Viyash. All Rights Reserved.